Ginkgo Bioworks Holdings Inc Stock Price, News & Analysis

Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) have expanded their collaboration with the CDC to enhance the Traveler-based Genomic Surveillance program. The initiative, initially focused on SARS-CoV-2, now includes monitoring for influenza viruses in preparation for the 2023-2024 flu season. This pilot study aims to provide vital insights into viral trends by sampling international travelers at major U.S. airports. The data collected will assist in selecting influenza vaccine viruses and bolster the public health response to seasonal influenza while continuing to track COVID-19 variants.

Ginkgo Bioworks (NYSE: DNA) announced preliminary performance updates for 2022, anticipating total revenue within the range of $460-480 million. The company reported a year-end cash balance of approximately $1.3 billion, enhancing its liquidity amidst economic challenges. Ginkgo expects to add 55-60 new Cell Programs and noted growth in biopharma customer engagement, particularly through the launch of Ginkgo Enzyme Services and the opening of Bioworks7 for mammalian cell engineering. A detailed financial report is set for March 2023.

On January 9, 2023, Prokarium and Ginkgo Bioworks (NYSE: DNA) announced their partnership to create a bactofection platform for delivering RNA-based therapeutics. This innovative gene delivery system utilizes genetically modified Salmonella bacteria to target and transfer therapeutic agents directly into mammalian cells, circumventing challenges associated with viral delivery methods. The collaboration aims to unlock new possibilities in immuno-oncology and enhance treatment options for cancer. Both companies emphasize the potential of this approach to revolutionize therapeutic modalities.

Ginkgo Bioworks (NYSE: DNA) has announced the opening of Bioworks7, a new facility in Boston aimed at enhancing its capabilities in biopharmaceutical manufacturing and mammalian programming. This expansion increases the company's capacity to support partners in cell and gene therapy and lowers costs associated with biological design. The Bioworks7 facility spans 6,600 square feet and features advanced robotics for stem cell engineering. Ginkgo's growth is further backed by new team expertise and recent partnerships with major biotech firms.

Esperovax and Ginkgo Bioworks (NYSE: DNA) have formed a partnership to develop circular RNAs (circRNAs) targeted at colorectal cancer. This collaboration focuses on using circRNAs to deliver therapeutic payloads that induce cell death specifically in cancerous cells, minimizing harm to healthy cells. Ginkgo's high-throughput screening and computational approaches will optimize Esperovax's mechanisms for therapeutic delivery. Ginkgo's expertise in cell and gene therapy enhances their capacity to innovate in RNA therapeutics, addressing critical needs in oncology.

Ginkgo Bioworks (NYSE: DNA) announced that CEO Jason Kelly will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 11:15 a.m. PT. Kelly will discuss Ginkgo's biopharma capabilities, including its Ginkgo Enzyme Services and high throughput pooled screening for CAR-T designs. The company offers end-to-end services in cell programming across various sectors, including pharmaceuticals and food. Further details, including a webcast link, will be available on their investor relations website.

Ginkgo Bioworks (NYSE: DNA) and Botswana's Ministry of Health have signed a Memorandum of Understanding to enhance biosecurity in Botswana. The collaboration aims to equip local health institutions with advanced biosecurity tools, training, and data infrastructure. This initiative focuses on developing pathogen monitoring programs at key locations and reinforcing Botswana's public health capabilities. Both parties recognize the necessity of international cooperation for effective biosecurity in response to emerging biological threats.

On December 8, 2022, Ginkgo Bioworks (NYSE: DNA) announced the launch of Ginkgo Enzyme Services, a platform aimed at enhancing enzyme engineering through machine learning and high-throughput screening. This service will assist R&D teams in identifying and optimizing novel enzyme activities for various industries, including pharmaceuticals and agriculture. A virtual event on December 15, 2022 will further detail this service. Ginkgo's innovative approach supports cost-effective and environmentally friendly enzyme production, potentially impacting market dynamics.

Ginkgo Bioworks (NYSE: DNA) announced the granting of 18,173,253 restricted stock units as part of its recent employee compensation strategy related to the acquisitions of Bayer CropScience LP and Zymergen Inc. Specifically, 9,868,143 units were awarded to former Bayer employees, and 8,305,110 units to former Zymergen employees. These grants were issued without stockholder approval as inducements to new hires. Vesting schedules vary by employee type, with some units vesting fully upon termination without cause. This move aims to bolster employee retention and align interests.